Icahn Tries To Rain On Genzyme's Investor Day Parade With Proxy Seeking Termeer's Ouster
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme CEO and Chairman Termeer highlighted investor day presentation with five-point plan for enhancing shareholder value, including $2 billion stock repurchase plan.
You may also be interested in...
Solomon To Step Aside As Forest Exec; Icahn Wins Another Victory
President and CEO of Forest Laboratories Howard Solomon will retire at the end of the year. Activist investor Carl Icahn has long inveighed against the 85 year-old exec. This could signal a renewed effort to get Forest back on track, now that its Lexapro losses have slashed revenue and a Namenda expiry looms.
Following Through On Prior Plan, Genzyme Sells Off Genetic Testing Unit
Sale of Genzyme Genetics for $925 million to LabCorp seen as enhancing the biotech's potential purchase value.
Following Through On Prior Plan, Genzyme Sells Off Genetic Testing Unit
Sale of Genzyme Genetics for $925 million to LabCorp seen as enhancing the biotech's potential purchase value.